Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2020 | 2 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20.
Lancet Neurol. 2017.
PMID: 29066163
Clinical Trial.
Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; REGAIN study group.
Mantegazza R, et al.
Ann Clin Transl Neurol. 2020 Aug;7(8):1327-1339. doi: 10.1002/acn3.51121. Epub 2020 Jul 22.
Ann Clin Transl Neurol. 2020.
PMID: 32700461
Free PMC article.
Clinical Trial.
Item in Clipboard
'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group.
Vissing J, et al.
J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18.
J Neurol. 2020.
PMID: 32189108
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite